We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.30 | 0.68% | 44.24 | 44.47 | 43.728 | 43.87 | 13,247,504 | 00:58:24 |
From May 2019 to May 2024
By Chelsey Dulaney
Bristol-Myers Squibb Co. agreed to buy the global rights to Dual Therapeutics LLC's cancer treatment.
Closely held Dual Therapeutics is developing a cancer therapeutic that more effectively targets cancer cells and spares normal cells.
Bristol-Myers Squibb will pay an undisclosed upfront fee, plus development costs, for global rights to develop and commercialize the treatment. Dual Therapeutics also could receive more than $225 million in milestone payments if the treatment secures regulatory approval.
Bristol-Myers already has a portfolio of cancer drugs. It makes Opdivo, a new drug that enlists the body's own immune defenses in the fight against cancer.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
(END) Dow Jones Newswires
January 08, 2016 08:35 ET (13:35 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
